Twist Bioscience (TWST) Stock Overview
Manufactures and sells synthetic DNA-based products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TWST Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Twist Bioscience Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$49.24 |
| 52 Week High | US$51.80 |
| 52 Week Low | US$23.30 |
| Beta | 2.27 |
| 1 Month Change | 41.74% |
| 3 Month Change | 62.67% |
| 1 Year Change | -5.85% |
| 3 Year Change | 107.76% |
| 5 Year Change | -70.67% |
| Change since IPO | 251.71% |
Recent News & Updates
Recent updates
Twist Bioscience: Ingenious Product Still Lacks Compelling Use Cases
Feb 02Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 30%
Jan 14
Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 31%
Oct 09Twist Bioscience Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Aug 07Little Excitement Around Twist Bioscience Corporation's (NASDAQ:TWST) Revenues As Shares Take 28% Pounding
Aug 06We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth
Jul 28Investors Don't See Light At End Of Twist Bioscience Corporation's (NASDAQ:TWST) Tunnel And Push Stock Down 25%
Jun 01We're Interested To See How Twist Bioscience (NASDAQ:TWST) Uses Its Cash Hoard To Grow
Apr 25
Cutting-edge DNA Synthesis Platform And Cost Reductions Will Power Future Market Expansion
Twist Bioscience's innovative DNA synthesis platform and strategic process improvements aim to drive revenue growth and enhance net margins.Why Investors Shouldn't Be Surprised By Twist Bioscience Corporation's (NASDAQ:TWST) 26% Share Price Plunge
Mar 02Twist Bioscience: Valuation Is Weighing On The Stock
Feb 06Twist Bioscience (NASDAQ:TWST) Is In A Strong Position To Grow Its Business
Dec 26Twist Bioscience Corporation's (NASDAQ:TWST) Shareholders Might Be Looking For Exit
Nov 30Twist Bioscience: Path To Profitability Beginning To Take Shape
Nov 29Twist Bioscience: A Post-Earnings Assessment
Nov 18Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
Nov 08Twist Bioscience (NASDAQ:TWST) Is In A Strong Position To Grow Its Business
Sep 25Investors Aren't Buying Twist Bioscience Corporation's (NASDAQ:TWST) Revenues
Aug 20Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)
Aug 04Twist Bioscience: Growing Customer Base And Technology Platform Make Me Like This Stock
Jul 26We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth
Jun 10Twist Bioscience Corporation (NASDAQ:TWST) Shares Fly 29% But Investors Aren't Buying For Growth
May 04Shareholder Returns
| TWST | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 19.9% | -0.6% | -3.0% |
| 1Y | -5.9% | 22.1% | 10.3% |
Return vs Industry: TWST underperformed the US Biotechs industry which returned 22.1% over the past year.
Return vs Market: TWST underperformed the US Market which returned 10.3% over the past year.
Price Volatility
| TWST volatility | |
|---|---|
| TWST Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TWST has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TWST's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 979 | Emily Leproust | www.twistbioscience.com |
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.
Twist Bioscience Corporation Fundamentals Summary
| TWST fundamental statistics | |
|---|---|
| Market cap | US$3.02b |
| Earnings (TTM) | -US$76.58m |
| Revenue (TTM) | US$391.56m |
Is TWST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TWST income statement (TTM) | |
|---|---|
| Revenue | US$391.56m |
| Cost of Revenue | US$189.42m |
| Gross Profit | US$202.13m |
| Other Expenses | US$278.72m |
| Earnings | -US$76.58m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.25 |
| Gross Margin | 51.62% |
| Net Profit Margin | -19.56% |
| Debt/Equity Ratio | 3.3% |
How did TWST perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/07 02:43 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Twist Bioscience Corporation is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Gaurav Goparaju | Berenberg |